Abstract
Adequate dosing of lenalidomide in Chronic Lymphocytic Leukemia (CLL) remains unclear. This study determined maximum tolerated dose (MTD) in relapsed CLL patients (Cohort A) and patients achieving a partial response (PR) or better to recent therapy (Cohort B). Thirty-seven patients were enrolled. MTD was 2.5. mg followed by 5.0. mg continuous. In Cohort A, tumor flare grade 1-2 occurred in 15 patients (50%) and grade 3 in 1 patient (3%). Cohort A had 19 of 23 evaluable (83%) patients, 4 PR (17%) and 15 (65%) stable disease (SD), Cohort B had 6 of 7 patients (86%) with SD. Despite overall response rate not being high, many patients remained on therapy several months with SD.
Original language | English |
---|---|
Pages (from-to) | 1025 |
Number of pages | 1 |
Journal | Leukemia Research |
Volume | 38 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2014 |
Keywords
- Chronic Lymphocytic Leukemia
- Lenalidomide
- Maintenance
- Relapse
- Tumor flare